Projected Burden of Bloodstream Infections and the Impact of Molecular Rapid Diagnostic Testing in England and the United States (2025-2029)

This study projects a significant rise in bloodstream infections in England and the US from 2025 to 2029, demonstrating that widespread adoption of molecular rapid diagnostic tests could save over 9,700 lives and reduce healthcare costs in both nations.

The Gist

Imagine your body is a bustling city. Sometimes, a tiny, invisible invader (a bacteria or fungus) slips into the bloodstream, which is like the city's main highway system. When this happens, it causes a Bloodstream Infection (BSI). This is a medical emergency that can shut down the city's power grid (your organs) very quickly.

The problem is that doctors often have to guess which invader is causing the trouble. They have to wait for a "slow-motion" test (traditional lab culture) that can take 24 to 48 hours to grow the bug so they can see what it is. In the meantime, they have to throw a "net" of broad-spectrum antibiotics at the patient, hoping it catches the right bad guy. This is like trying to put out a fire with a garden hose when you don't know if it's a grease fire or an electrical fire. It's risky, expensive, and sometimes the fire keeps burning.

Enter the "Super-Speed Detective": Molecular Rapid Diagnostic Testing (mRDT).

This paper is a forecast for the next five years (2025–2029) in two major cities: England and the United States. It asks: What happens if we keep guessing, and what happens if we give every doctor a "Super-Speed Detective" that can identify the exact bug in just a few hours?

Here is the breakdown of the findings in simple terms:

1. The Growing Traffic Jam (The Problem)

The authors looked at population trends and realized that the number of these infections is going to skyrocket.

• The Analogy: Think of the population as a city that is getting older and bigger. Older people are more like "old buildings" that are more fragile and prone to catching fire.
• The Numbers: By 2029, they predict there will be over 1 million of these infections in England and over 6 million in the US.
• The Cost: Currently, treating these infections without the "Super-Speed Detective" is costing billions. It's like paying for a fire department that arrives too late, causing more damage and requiring more expensive repairs.

2. The "Super-Speed Detective" (The Solution)

The paper focuses on a specific type of test (Cobas® Eplex) that acts like a high-tech scanner. Instead of waiting two days for the bug to grow, it identifies the germ and its weaknesses in a few hours.

• How it helps: Once the doctor knows exactly who the invader is, they can switch from the "broad net" to a "sniper shot." They use the exact right antibiotic immediately.
• The Result: The patient gets better faster, stays in the hospital for fewer days, and is less likely to die.

3. The Forecast: What Happens if We Adopt This?

The researchers ran a simulation to see what would happen if hospitals in England and the US started using this technology widely over the next five years.

In England:

• Lives Saved: About 2,200 lives would be saved. That's like filling a large stadium with people who would have otherwise passed away.
• Money Saved: The healthcare system would save about £50 million. It's a "win-win": you save lives and you save money because patients leave the hospital sooner.

In the United States:

• Lives Saved: About 7,500 lives would be saved.
• Money Saved: The US healthcare system would save over $500 million.

4. Why This Matters Now

The paper argues that we are currently stuck in a "waiting game." We have the technology to solve the problem, but many hospitals are still using the old, slow methods.

• The Metaphor: Imagine you have a GPS that can tell you the fastest route to the hospital in 10 seconds, but half the doctors are still using a paper map from 1990. This paper says, "Stop using the paper map! The GPS is here, it's cheaper in the long run, and it saves lives."

The Bottom Line

This study is a wake-up call. It predicts that without change, the burden of these infections will get heavier and more expensive. However, if we equip doctors with these "Super-Speed Detectives" (molecular tests), we can turn the tide. We can save thousands of lives and save billions of dollars by treating patients faster and smarter.

In short: Faster diagnosis = Faster cure = Fewer deaths + Lower bills. It's time to upgrade the system.

Technical Summary

1. Problem Statement

Bloodstream infections (BSIs) represent a major cause of global morbidity and mortality, imposing a significant financial burden on healthcare systems. A critical barrier to effective treatment is the "diagnostic gap" in pathogen identification. Standard microbiological practices (culture followed by MALDI-ToF MS) often require 24–48 hours, necessitating the use of empiric broad-spectrum antibiotics. This delay leads to:

• Increased mortality due to delayed targeted therapy.
• Development of antimicrobial resistance.
• Higher healthcare costs due to prolonged hospital stays and adverse events (e.g., Clostridioides difficile infection, acute kidney injury).

Key Evidence Gaps:

• Data Scarcity: There is a lack of current, national-level BSI incidence data, particularly in the US (relying on a 2003–2005 Minnesota study).
• Forward-Looking Projections: Previous studies established per-patient cost-effectiveness of Molecular Rapid Diagnostic Tests (mRDT) but failed to quantify the total national-level burden and the potential impact of widespread adoption over the next decade, accounting for demographic shifts.

2. Methodology

The study employed a modeling approach to project BSI incidence, mortality, and costs from 2025 to 2029 for England and the US.

Data Sources & Inputs:

• England: Utilized 2017 national surveillance data (broken down by age and sex) combined with Office for National Statistics (ONS) demographic projections.
• US: Utilized a 2003–2005 population-based study from Olmsted County, Minnesota, as the baseline. This rate was adjusted to 2017 levels and then scaled to US demographic projections from the Census Bureau.
• Incidence Growth: Assumed a base-case annual increase in BSI incidence of 3.0% (sensitivity analyses tested 1.0% and 5.0%).
• Intervention: Modeled the introduction of Cobas® Eplex Blood Culture Identification (BCID) panels (an mRDT) as an adjunct to MALDI-ToF MS in hospitals currently not using mRDT.
• Adoption Assumptions:
  • England: Assumed 0% current mRDT uptake; modeled a transition to 100% adoption.
  • US: Assumed 50% current mRDT uptake (based on 2023 survey data extrapolated); modeled the remaining 50% transitioning to 100% adoption.
• Clinical Parameters: Derived from a previous cost-effectiveness study [13], incorporating reductions in Length of Stay (LOS), mortality, and adverse events associated with earlier pathogen identification and antimicrobial stewardship programs (ASP).

Analytical Approach:

• Projection: Applied incidence rates to population demographics to estimate total BSI cases.
• Impact Modeling: Calculated lives saved and cost savings by applying the per-patient efficacy of mRDT (reduced LOS, reduced mortality) to the projected case volumes.
• Scenario Analysis: Tested uncertainty by varying BSI growth rates, mRDT uptake trajectories (linear vs. immediate), and cost/mortality inputs (±10%).

3. Key Contributions

• First National Projections: Provides the first forward-looking, national-level estimates of BSI burden for England and the US through 2029, highlighting the compounding effect of demographic aging and rising incidence.
• Quantification of "Diagnostic Inertia": Moves beyond per-patient economics to quantify the aggregate human and economic cost of delaying mRDT adoption at a national scale.
• Policy Framework: Offers a decision-support framework for policymakers and hospital administrators, demonstrating that mRDT adoption is not only clinically beneficial but cost-saving (negative cost) for healthcare systems.

4. Key Results

Projected Burden (2025–2029):

• England:
  • Total Cases: ~1.02 million.
  • Total Deaths: ~116,538.
  • Total Cost (Current Care): £14.6 billion (Note: The abstract mentions £14.6 million, but Table 3 and the text clarify this is £14.6 billion or £14,589m).
• United States:
  • Total Cases: ~6.24 million.
  • Total Deaths: ~697,289.
  • Total Cost (Current Care): $221 billion (Note: The abstract mentions $221 million, but Table 5 and text clarify this is $221 billion or $221,000m).

Impact of mRDT Adoption (Cobas Eplex BCID):

• Lives Saved (5-Year Period):
  • England: 2,219 lives saved (1.9% reduction in mortality).
  • US: 7,554 lives saved.
• Cost Savings (5-Year Period):
  • England: £50.9 million saved.
  • US: $512 million saved.
• Mechanism: Savings are driven by reduced Length of Stay (LOS) and decreased exposure to broad-spectrum antibiotics (reducing AKI and C. diff infections), which offset the cost of the tests.

Scenario Analysis:

• Results were robust across variations. Even in conservative scenarios (e.g., linear uptake from 20% to 100% over 5 years, or 1% BSI growth), the intervention remained cost-saving and saved thousands of lives (minimum ~4,682 lives saved and $317 million saved in the US).

5. Significance and Conclusion

• Clinical Imperative: The study argues that waiting for definitive large-scale clinical trial data on mortality reduction is impractical given the small effect size required for statistical significance. Decision models synthesizing intermediate outcomes (time to therapy) provide sufficient evidence to justify immediate adoption.
• Economic Viability: Contrary to the perception that new diagnostics increase costs, this analysis demonstrates that widespread mRDT adoption is cost-saving for healthcare systems in both England and the US.
• Public Health Strategy: The findings support the integration of mRDT into standard care pathways and Antimicrobial Stewardship Programs (ASPs) to mitigate the growing burden of BSIs driven by an aging population.
• Limitations: The study relies on older US data (Olmsted County) and assumes similar age/sex risk gradients between the US and England. Mortality estimates are considered conservative as they do not fully adjust for the specific age-related mortality risks of the aging population.

Final Conclusion: The authors conclude there is a compelling argument to increase mRDT uptake. Doing so could save over 9,700 lives and reduce healthcare expenditures by over $560 million (combined) in the next five years, representing a critical opportunity to improve patient safety and system efficiency.